Motif, the clinical stage biopharmaceutical company specializing in developing novel antibiotics, has announced the topline results of an independent report from microbiology specialists, JMI Laboratories.
The report shows that iclaprim is effective in vitro against a range of Gram-positive bacteria, including Staphylococcus aureus , one of the key causes of acute bacterial skin and skin structure infection (ABSSSI) and hospital-acquired bacterial pneumonia (HABP).
The recently completed laboratory study tested iclaprim against more than 2000 bacterial strains, including 1178 strains of Staphylococcus aureus collected in 2014 from patients in the USA, Europe, Asia Pacific and Latin America. Iclaprim was found to be 16-fold more potent than trimethoprim, the only other antibacterial dihydrofolate reductase inhibitor (DHFRi) administered alone in today’s market.
Reported minimum inhibitory concentrations (MICs) demonstrated that iclaprim is active against Staphylococcus aureus at very low concentrations. The MIC50, the minimum concentration of iclaprim required to kill 50% of tested bacteria, was 0.06 µg/mL and the MIC90, the minimum concentration of iclaprim required to kill 90% of tested bacteria, was 0.12 µg/mL.
Comparing this with data for other antibiotics against the same 1178 strains of Staphylococcus aureus , 1 µg/mL of vancomycin and 1 µg/mL of linezolid was required to meet the MIC50 and MIC90 levels. Against methicillin-resistant Staphylococcus aureus (MRSA), iclaprim was also highly active: the MIC50 was 0.06 µg/mL and the MIC90 was 0.5 µg/mL.
The tests were conducted according to Clinical and Laboratory Standards Institute (CLSI) methods. CLSI develops clinical laboratory testing standards based on input from and consensus among industry, government, and health care professionals around the world.
Dr David Huang, Chief Medical Officer at Motif, commented: “These encouraging new results confirm the board’s confidence in developing iclaprim to treat ABSSSI and HABP. We believe that iclaprim will prove to be an important option for treating these life threatening infections where currently available treatments are not fully effective due to resistance or side-effects.”